| 中文名称 |
α-hederin
|
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 中文别名 |
ALPHA-常春藤皂甙;Alpha常春藤苷;Alpha-常春藤苷;ALPHA-常春藤素(P);a-常春藤皂苷;α-常春藤;α-常春藤苷;α-常春藤皂苷;阿尔法-常春藤皂甙;白头翁皂苷;Alpha-常春藤皂苷;常春藤皂甙
|
||||||||||||
| 英文名称 |
α-hederin
|
||||||||||||
| 英文别名 |
ALPHA-HEDERIN;SAPINDOSIDE A;HEDERIN;HELIXIN;HEDERIN, ALPHA-;(3-beta,4-alpha)-nopyranosyl)oxy)-23-hydroxy;akebiasaponinpd;akebosidestc;alpha-hederine;glycosidel-e1;HEDERIN, ALPHA-(P) PrintBack;Olean-12-en-28-oicacid, 3-[[2-O-(6-deoxy-a-L-mannopyranosyl)-a-L-arabinopyranosyl]oxy]-23-hydr...;α-Hederin;A-HEDERIN;dipsacobioside;Hederoside B;hederosidec;koronaroside A;nepalin2;taurosidee;(3β,4α)-3-[[2-O-(6-Deoxy-α-L-mannopyranosyl)-α-L-arabinopyranosyl]oxy]-23-hydroxyolean-12-en-28-oic acid;[
""
];CID 121241172;.alpha.-Hederin;NSC106553;STL454351;NCI60_000155;3-{[2-O-(6-Deoxyhexopyranosyl)pentopyr
|
||||||||||||
| Cas No. |
27013-91-8
|
||||||||||||
| 分子式 |
C41H66O12
|
||||||||||||
| 分子量 |
750.96
|
||||||||||||
| 包装储存 |
|
| 生物活性 |
alpha-Hederin (α-Hederin), a monodesmosidic triterpenoid saponin, exhibits promising antitumor potential against a variety of human cancer cell lines. alpha-Hederin could inhibit the proliferation and induce apoptosis of gastric cancer accompanied by glutathione decrement and reactive oxygen species generation via activating mitochondrial dependent pathway. |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 性状 |
Solid |
||||||||||||
| 体外研究(In Vitro) |
alpha-Hederin (α-Hederin) is cytotoxic and inhibits proliferation in both cel lines at rather low concentrations. alpha-Hederin (α-Hederin)reduces the mitotic activity in treated cells. Medlife has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||
| 体内研究(In Vivo) |
alpha-Hederin (α-Hederin) has preventive effect on sensitized rats like thymoquinone. It may intervene in miRNA-126 expression, which consequently could interfere with IL-13 secretion pathway leading to a reduction in inflammatory responses. Medlife has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||
| 运输条件 |
Room temperature or refrigerated transportation. |
||||||||||||
| 储存方式 |
|
||||||||||||
| 结构分类 | |||||||||||||
| 来源 | |||||||||||||
| 参考文献 |
|
| 溶解度数据 |
体外研究:
DMSO : ≥ 100 mg/mL (133.16 mM) H2O : < 0.1 mg/mL (insoluble) * "≥" means soluble, but saturation unknown. 配制储备溶液
*
产品不同,其溶解度不同。建议根据产品选择合适的溶剂配制储备溶液;配成溶液后,建议分装保存,避免反复冻融造成的产品失效。 体内研究:
建议根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都建议先按照 体外研究 方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
*
|
|---|
1:一般建议:溶解度为Medlife测试数据,可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异,仅做参考,具体以实验方案为准。
2:储存条件:粉末-20°C一般情况可以保存3年,溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异,请细致阅读产品信息,并辅助参考相关文献描述。
Copyright © 2025 陌孚医药 All rights reserved 未经授权禁止拷贝本站所有资料,如有违反,将追究法律责任。
沪ICP备2023012080号 |
沪公网安备31011402010657号
扫码关注公众号